Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

ATTR-ACT

In patients with transthyretin amyloid cardiomyopathy, tafamidis, as compared to placebo, reduced all-cause mortality (29.5% vs. 42.9%; HR 0.70, 95% CI 0.51-0.96) and reduced the rate of cardiovascular-related hospitalizations (0.48 per year vs. 0.70 per year; RR 0.68, 95% CI 0.56-0.81). Tafamidis also reduced the decline in distance for the 6 minute walk test (p < 0.001) and reduced the rate of decline in KCCQ-OS score (p < 0.001). The incidence and types of adverse events were similar in the two groups.